Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by BioPorto A/S

US News & World Report Webinar “New Frontiers in Kidney Care” features NGAL biomarker
From BioPorto A/S
Via GlobeNewswire
ProNephro AKI™ (NGAL), early detection test for Acute Kidney Injury, now commercially available to US Labs through BioPorto’s collaboration with Roche Diagnostics.
From BioPorto A/S
Via GlobeNewswire
BioPorto attends the Association for Diagnostics & Laboratory Medicine meeting, where NGAL and Acute Kidney Injury will be a key focus among participants.
From BioPorto A/S
Via GlobeNewswire
BioPorto announces the publication of urinary NGAL reference ranges in healthy adult and pediatric individuals
From BioPorto A/S
Via GlobeNewswire
BioPorto Sponsors Exhibits to Showcase Launch of ProNephro AKI in the U.S. and Ongoing Marketing of The NGAL Test to Clinicians at Major Healthcare Conferences
From BioPorto A/S
Via GlobeNewswire
First Patient In - BioPorto Initiates Patient Enrollment for US Study of ProNephro AKI (NGAL)™ for Adult Use at Massachusetts General Hospital
From BioPorto A/S
Via GlobeNewswire
BioPorto Enters Global Distribution Partnership with Beckman Coulter for Acute Kidney Injury NGAL Tests
From BioPorto A/S
Via GlobeNewswire
BioPorto Presenting FDA-cleared ProNephro AKI (NGAL) at ASN Kidney Week 2024 Conference
From BioPorto A/S
Via GlobeNewswire
BioPorto is proud to have Nine of the top-ten best US Children’s hospitals as customers of NGAL
From BioPorto A/S
Via GlobeNewswire
BioPorto Announces Appointment of National Principal Investigator and Selection of CRO for Upcoming USA ICU Adult AKI Clinical Study
From BioPorto A/S
Via GlobeNewswire
BioPorto Announces NIH-Funded Study to Explore the Ability of Renal Biomarkers in Predicting Severe AKI, Advancing Beyond NLP-based AI Algorithms
From BioPorto A/S
Via GlobeNewswire
BioPorto to Debut FDA Approved ProNephro AKI at Upcoming ADLM 2024 Clinical Lab Expo
From BioPorto A/S
Via GlobeNewswire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.